CVS Health Corporation is rated a Buy with a strong turnaround driving industry-leading results. Learn more about CVS stock ...

CVS Health’s narrative has shifted with a slightly higher fair value estimate, nudging from about $91.50 to roughly $92.40 ...

As South Carolina public health officials work to stop the spread of measles following the current outbreak in the state, CVS ...

Dec 9 (Reuters) - CVS Health on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, ...

The healthcare giant expects its turnaround efforts to pay off as it raised its full-year outlook and expects that momentum ...

Medical experts say getting a yearly flu vaccination is the best way to prevent flu and its potentially serious complications ...

Fintel reports that on December 12, 2025, Bernstein maintained coverage of CVS Health (NYSE:CVS) with a Market Perform ...

The healthcare company says it expects to post a narrower per-share loss in 2025.

Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...

It’s part of a larger battle between Louisiana officials and big health care companies over prescription drug prices.

Shares of diversified healthcare company CVS Health (NYSE:CVS) jumped 3.2% in the morning session after the company raised ...